Last 12 months
Inside the activity.
0 purchase rows · 64 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 34 |
| Jan 2026 | 0 | 21 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC |
GIVEN DOUGLAS BDirector
|
Exercise / conversionCommon Stock | 7,000 | $4.75 | $33,250.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 5 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC |
GIVEN DOUGLAS BDirector
|
Exercise / conversionCommon Stock | 10,000 | $2.62 | $26,200.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 4 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC |
GIVEN DOUGLAS BDirector
|
Exercise / conversionCommon Stock | 18,000 | $2.19 | $39,420.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 3 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC |
GIVEN DOUGLAS BDirector
|
Exercise / conversionCommon Stock | 30,000 | $5.19 | $155,700.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 00:08 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-014235 · doc4.xml · derivative · entry 3 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,500 Underlying: Common Stock · 42,500 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 00:08 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 42,500 | $18.98 | $806,650.00 |
DisclosureSEC source: 0001209191-19-014235 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,606 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 00:08 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 42,500 | $2.01 | $85,425.00 |
DisclosureSEC source: 0001209191-19-014235 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:32 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 3,000 | $18.05 | $54,150.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.92 to $18.18, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:09 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-011829 · doc4.xml · derivative · entry 4 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,000 Underlying: Common Stock · 42,500 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:09 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 42,500 | $17.98 | $764,150.00 |
DisclosureSEC source: 0001209191-19-011829 · doc4.xml · nonDerivative · entry 3 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,606 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.98 to $18.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:09 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 42,500 | $2.01 | $85,425.00 |
DisclosureSEC source: 0001209191-19-011829 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 687,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:12 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-19-011831 · doc4.xml · derivative · entry 3 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 8,000 shares Expires 2020-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:12 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 8,000 | $18.00 | $144,000.00 |
DisclosureSEC source: 0001209191-19-011831 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,607 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 01:12 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
Exercise / conversionCommon Stock | 8,000 | $5.20 | $41,600.00 |
DisclosureSEC source: 0001209191-19-011831 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 21, 2019 01:09 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 26,250 | $17.67 | $463,837.50 |
DisclosureSEC source: 0001209191-19-011829 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,606 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.61 to $17.79, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · derivative · entry 10 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,500 Underlying: Common Stock · 42,500 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 42,500 | $17.06 | $725,050.00 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 7 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,856 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 42,500 | $2.01 | $85,425.00 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 6 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · derivative · entry 9 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,000 Underlying: Common Stock · 11,667 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 57,000 | $16.48 | $939,360.00 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 5 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,856 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 97,167 | $15.66 | $1,521,635.22 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 4 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 727,856 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.23 to $16.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 11,667 | $2.62 | $30,567.54 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 3 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · derivative · entry 8 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,667 Underlying: Common Stock · 11,667 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 46,167 | $15.34 | $708,201.78 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,356 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $15.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 01:58 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 11,667 | $2.62 | $30,567.54 |
DisclosureSEC source: 0001209191-19-009534 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 859,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2019 Filed Feb 8, 2019 01:35 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 22,500 | $14.48 | $325,800.00 |
DisclosureSEC source: 0001209191-19-008329 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,856 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 00:51 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 28,500 | $13.85 | $394,725.00 |
DisclosureSEC source: 0001209191-19-006623 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,356 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.62 to $14.14, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 01:53 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 17,500 | $13.15 | $230,125.00 |
DisclosureSEC source: 0001209191-19-005261 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 898,856 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.28, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 01:53 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 152,000 | $13.59 | $2,065,680.00 |
DisclosureSEC source: 0001209191-19-005261 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 916,356 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.30 to $14.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 01:46 UTC |
GIVEN DOUGLAS BDirector
|
SaleCommon Stock | 3,000 | $13.58 | $40,740.00 |
DisclosureSEC source: 0001209191-19-005259 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.32 to $14.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 18, 2019 Filed Jan 19, 2019 00:02 UTC |
O'Brien PatrickGeneral Counsel
|
SaleCommon Stock | 72,000 | $14.43 | $1,038,960.00 |
DisclosureSEC source: 0001209191-19-004629 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,000 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.10 to $14.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 17, 2019 Filed Jan 19, 2019 00:00 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 81,875 | $14.55 | $1,191,281.25 |
DisclosureSEC source: 0001209191-19-004624 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,607 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.28 to $14.72, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:24 UTC |
Li ZhenSnr. VP, Chem and Non-Clin Dev
|
SaleCommon Stock | 40,500 | $14.34 | $580,770.00 |
DisclosureSEC source: 0001209191-19-004005 · doc4.xml · nonDerivative · entry 1 Li Zhen · CIK 0001729510 · Snr. VP, Chem and Non-Clin Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,700 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $14.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:18 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001209191-19-004003 · doc4.xml · derivative · entry 5 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,334 Underlying: Common Stock · 1,000 shares Expires 2019-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:18 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 11,666 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-19-004003 · doc4.xml · derivative · entry 4 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,334 Underlying: Common Stock · 11,666 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:18 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 42,666 | $14.40 | $614,390.40 |
DisclosureSEC source: 0001209191-19-004003 · doc4.xml · nonDerivative · entry 3 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,068,356 F1 · kind: These shares were sold pursuant to a 10b5-1 plan adopted by the reporting person. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.03 to $14.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:18 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 1,000 | $6.20 | $6,200.00 |
DisclosureSEC source: 0001209191-19-004003 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 17, 2019 01:18 UTC |
GIVEN BRUCE DChief Operating Officer
|
Exercise / conversionCommon Stock | 11,666 | $2.62 | $30,564.92 |
DisclosureSEC source: 0001209191-19-004003 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110,022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2019 Filed Jan 11, 2019 23:15 UTC |
Waddill William D.Director
|
SaleCommon Stock | 8,500 | $14.77 | $125,545.00 |
DisclosureSEC source: 0001209191-19-003464 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 01:16 UTC |
Ferrari MauroDirector
|
GrantCommon Stock | 3,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001548 · doc4.xml · nonDerivative · entry 1 Ferrari Mauro · CIK 0001506045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,656 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:53 UTC |
GIVEN BRUCE DChief Operating Officer
|
SaleCommon Stock | 20,000 | $11.98 | $239,600.00 |
DisclosureSEC source: 0001209191-19-001472 · doc4.xml · nonDerivative · entry 2 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,356 F2 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.69 to $12.16, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:55 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
SaleCommon Stock | 8,333 | $11.98 | $99,829.34 |
DisclosureSEC source: 0001209191-19-001476 · doc4.xml · nonDerivative · entry 2 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,482 F2 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.69 to $12.16, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:15 UTC |
PERRY MICHAEL SDirector
|
GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001543 · doc4.xml · nonDerivative · entry 1 PERRY MICHAEL S · CIK 0001250379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:18 UTC |
Waddill William D.Director
|
GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001551 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:13 UTC |
GIVEN DOUGLAS BDirector
|
GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001537 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,130 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:58 UTC |
O'Brien PatrickGeneral Counsel
|
GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001485 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:08 UTC |
Li ZhenSnr. VP, Chem and Non-Clin Dev
|
GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001522 · doc4.xml · nonDerivative · entry 1 Li Zhen · CIK 0001729510 · Snr. VP, Chem and Non-Clin Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,200 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:53 UTC |
GIVEN BRUCE DChief Operating Officer
|
GrantCommon Stock | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001472 · doc4.xml · nonDerivative · entry 1 GIVEN BRUCE D · CIK 0001219384 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118,356 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:55 UTC |
Myszkowski Kenneth AllenChief Financial Officer
|
GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001476 · doc4.xml · nonDerivative · entry 1 Myszkowski Kenneth Allen · CIK 0001486672 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,815 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:49 UTC |
Anzalone Christopher RichardDirector · Chief Executive Officer
|
GrantCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001467 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,142,455 F1 · shares: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that must be achieved within two years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole. F2 · balance_after: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.